TP53 and glioblastoma: Importantly, the genetic drivers of glioblastoma malignancy will probably affect the successful translational applicability of Treg targeting, as we observed a less pronounced Treg induction and response in the genetically distinct PDG-Ink4a and PDG-p53 glioblastoma models.